Nephrotic Syndrome
📧 Sign up to get email alerts when something new happens for Nephrotic Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-07-25FDA Approved: SPIRONOLACTONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for spironolactone submitted by Sun Pharmaceutical Industries, Inc., indicating an update to the…
-
FDA approval · 2019-07-12FDA Approved: ETHACRYNIC ACID — Original Application (TRUPHARMA LLC)
FDA approves the original ANDA for Ethacrynic acid by Trupharma LLC, enabling its generic distribution as a loop diuretic. The approval cove…
-
CLINICAL_TRIALS trial_result · 2019-05-10Clinical Trial Update: Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome [Phase 3]
Phase 3 trial update on ACTH for frequently relapsing and steroid-dependent nephrotic syndrome; results have been posted after completion.
-
FDA approval · 2019-05-03FDA Approved: FUROSEMIDE — Original Application (Eugia US LLC)
FDA approved an original ANDA for FUROSEMIDE by Eugia US LLC, confirming a generic version of the diuretic. This is a routine generic drug a…
-
FDA approval · 2019-04-24FDA Approved: BUMETANIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for Bumetanide from Upsher-Smith Laboratories, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-04-23FDA Approved: AZATHIOPRINE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for azathioprine from Rising Pharma Holdings, Inc., confirming a new generic form of the drug.
-
CLINICAL_TRIALS trial_result · 2019-03-26Clinical Trial Update: Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome [Phase 3]
A Phase 3 randomized trial comparing rituximab to mycophenolate mofetil in children with refractory nephrotic syndrome was terminated; resul…
-
FDA approval · 2019-02-26FDA Approved: CHLORTHALIDONE — Original Application (Chartwell RX, LLC)
The FDA approved Chartwell RX, LLC's original application for chlorthalidone, a generic diuretic. This enables marketing of the generic chlo…
-
CLINICAL_TRIALS trial_result · 2019-02-07Clinical Trial Update: Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children [Phase 4]
A Phase 4 clinical trial evaluated tacrolimus for treating primary nephrotic syndrome in children; results were posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-01-17Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome [Phase 3]
A Phase 3 clinical trial evaluating mizoribine for efficacy and safety in refractory nephrotic syndrome has completed.
-
FDA approval · 2018-08-08FDA Approved: LASIX — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for LASIX (furosemide) from Validus Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2018-07-20Clinical Trial Update: Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study
This completed Canadian incidence study examines the occurrence of steroid-induced osteoporosis in pediatric patients. It highlights the bur…
-
CLINICAL_TRIALS research · 2018-07-19Clinical Trial Update: Diagnostic and Prognostic Value of Miss-1 Study in Children and Adult With Nephrotic Syndrome MISSNEPHROTIQUE
This clinical trial update describes the MISSNEPHROTIQUE study evaluating the diagnostic and prognostic value of MISS-1 in children and adul…
-
FDA approval · 2018-07-18FDA Approved: SPIRONOLACTONE — Original Application (Zydus Lifesciences Limited)
FDA approved the Original Application (ANDA) for spironolactone from Zydus Lifesciences Limited, marking a generic version of the diuretic.
-
CLINICAL_TRIALS withdrawal · 2018-05-30Clinical Trial Update: Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study [Phase 2]
A Phase 2 pilot study testing low-dose interleukin-2 for steroid-dependent nephrotic syndrome in children has been withdrawn.
-
FDA approval · 2018-05-08FDA Approved: ETHACRYNIC ACID — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original generic application for Ethacrynic acid from Amneal Pharmaceuticals NY LLC.
-
FDA approval · 2018-04-30FDA Approved: BUMETANIDE — Original Application (Zydus Pharmaceuticals (USA) Inc.)
FDA approved Bumetanide as a generic via Original Application (ANDA 202900), confirming bioequivalence to the reference product. It is indic…
-
FDA approval · 2018-01-23FDA Approved: BUMETANIDE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Bumetanide under an Original Application for Upsher-Smith Laboratories, establishing a generic version of the loop diuretic.
-
CLINICAL_TRIALS trial_result · 2017-11-20Clinical Trial Update: Pharmacokinetics of Tacrolimus in Children [Phase 4]
Phase 4 study reporting the pharmacokinetics of tacrolimus in children with nephrotic syndrome; the trial sponsored by Shandong University h…
-
CLINICAL_TRIALS research · 2017-08-02Clinical Trial Update: Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome
Clinical trial update evaluating serum miRNA-30a in childhood nephrotic syndrome, focusing on steroid-resistant cases.
-
CLINICAL_TRIALS trial_result · 2017-08-01Clinical Trial Update: Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome [Phase 3]
Completed Phase 3 trial assessing the efficacy and safety of rituximab compared with calcineurin inhibitors in children with steroid-depende…
-
EMA withdrawal · 2017-07-18EMA Application withdrawn: Elmisol — ACE Pharmaceuticals BV
The EMA withdrew the application for Elmisol from ACE Pharmaceuticals BV in the nephrotic syndrome area.
-
FDA approval · 2017-07-14FDA Approved: FUROSEMIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for furosemide submitted by Hikma Pharmaceuticals USA Inc. The notice confirms regulatory approval o…
-
CLINICAL_TRIALS trial_result · 2017-07-06Clinical Trial Update: Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome [Phase 4]
A Phase 4 trial evaluating mycophenolate mofetil in pediatric steroid-dependent nephrotic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome [Phase 3]
Phase 3 trial evaluating low-dose corticosteroids in combination with Myfortic for nephrotic syndrome has completed.